For the second year in a row, metastatic melanoma (MM) research will be presented at the plenary session of the American Society of Clinical Oncology (ASCO) Annual meeting. Last year, the results of the second-line phase 3 data on the immunotherapy ipilimumab for MM, called the 020 trial, were presented in the plenary session. Your link text here.
